Will Big Pharma get the bug for microbiome therapies?
The exciting field of microbiome therapeutics offers many opportunities for ‘Big Pharma’ players that are staring over the exclusivity cliff, say Craig Thomson, Leena Contarino and Andrew Wells of HGF.
- Conference preview: 12th Pharma & Biotech Patent Litigation 27-01-2020
- Event preview: BIO-Europe returns to Hamburg 22-10-2019
- M&A: Year of the megadeal 30-09-2019
- IP portfolios: the five biggest headaches for in-house counsel 30-09-2019
- Secondary patents: Moscow mewl 30-09-2019
Latest biotechnology news
Codexis sues rival DNA tech company over TMs
27-05-2020
Protein engineering company Codexis has accused competitor Codex DNA of trademark infringement through the use of a “virtually identical” mark.
HGF promotes two to partner
11-05-2020
